sellNotable cluster of 4
Orbimed Advisors LLC sold $29M of ALPN
director at ALPINE IMMUNE SCIENCES, INC.. 1,546,347 shares at an average of $18.54, traded Dec 27, 2023, filed Dec 29, 2023.
Warning score
65Value
$29M
1,546,347 shares
Holdings after
264,315
-42% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +25Trade size$28.7M at market
- +10Share of holdings soldSold 42% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000947871-23-001189, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 27, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -162,576 | $19.96 | $3.2M | 3,493,485 | Dec 29, 2023 |
| Dec 27, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -18,922 | $19.96 | $378k | 406,609 | Dec 29, 2023 |
| Dec 28, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -26,872 | $19.82 | $533k | 3,466,613 | Dec 29, 2023 |
| Dec 28, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -3,128 | $19.82 | $62k | 403,481 | Dec 29, 2023 |
| Dec 28, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -1,195,683 | $18.32 | $22M | 2,270,930 | Dec 29, 2023 |
| Dec 28, 2023 | SOpen-market sale Common Stockindirect: See footnotes | -139,166 | $18.32 | $2.5M | 264,315 | Dec 29, 2023 |
Related signals
Other insiders at ALPINE IMMUNE SCIENCES, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | ALPNsell ALPINE IMMUNE SCIENCES, INC. | James N Topper director | $1,227 19 shares | -0% | |
| 25Weak | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $2.8M 118,000 shares | -50000% | |
| 65Notable | ALPINE IMMUNE SCIENCES, INC. | Peter A. Thompson director | $29M 1,546,347 shares | -42% | |
| 25Weak | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $20k 1,016 shares | -100% | |
| 50Moderate | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $1.9M 91,884 shares | -243% | |
| 32Weak | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $48k 2,402 shares | -100% | |
| 29Weak | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $292k 15,213 shares | -100% | |
| 40Moderate | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $1.1M 58,787 shares | -507% | |
| 43Moderate | ALPINE IMMUNE SCIENCES, INC. | Mitchell Gold Executive Chairman and CEO | $2.0M 118,000 shares | -108% | |
| 33Weak | ALPINE IMMUNE SCIENCES, INC. | James Paul Rickey See Remarks | $1.1M 70,811 shares | -111% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.